Abstract
MicroRNA-101 has been reported as an important factor in carcinogenesis of several malignant tumors. However, its actual role in prognosis among solid malignancies remains unclear. Accordingly, we performed this meta-analysis aiming to identify prognostic significance of miR-101 in solid tumor. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) or disease-free survival (DFS)/metastasis-free survival (MFS)/progression-free survival (PFS)/relapse-free survival (RFS)/time-to progression (TTP) were estimated with random effects or fixed effects models on the basis of heterogeneity. Subgroup analysis, sensitive analysis and meta-regression analysis were also conducted to clarify the possible confounding factors and investigate the source of heterogeneity. Publication bias was evaluated by using Begg’s and Egger’s tests. A total of 21 studies containing 3753 cases were selected into our quantitative analysis via electronic database search. A lower expression of miR-101 was significantly associated with worse OS (HR = 0.66, 95%CI [0.52–0.85], P = 0.001) and PFS (HR = 0.70, 95%CI [0.51–0.95], P = 0.023) in patients with solid tumor. The under-expression of miRNA-101 is a credible indicator of poorer prognosis in several of solid malignancies.
Highlights
MicroRNAs are a subset of small non-coding RNA molecules that are approximately 18–22 nucleotides in length
Inclusion criteria were as follows:1) studies exploring any of the solid tumor; 2) studies dealing with miR-101 expression and overall survival (OS)/disease-free survival (DFS)/progression-free survival (PFS)/relapse-free survival (RFS)/metastasis-free survival (MFS)/time-to progression (TTP); 3) studies that categorized patients into low- and high-expression groups based on the miR-101 expression; 4) studies providing hazard ratios (HRs) directly or key information to calculate HR indirectly, such as Kaplan-Meier curves and original survival data; 5) studies assessing miR-101 expression in tissue or blood
Genomewide miRNA expression profiling studies revealed that miR-101 is widely present in various tissues and organs, and its aberrant expression was reported in various cancers including HCC [14, 19, 20, 25], CRC[13, 30], breast cancer[23, 26], NSCLC[22], gliomas[28], and et al It is indubitable that miR-101 is an important cancer-related miRNA
Summary
MicroRNAs (miRNA, miRs) are a subset of small non-coding RNA molecules that are approximately 18–22 nucleotides in length. MiRNAs play crucial regulatory roles in gene expression at the post-transcriptional level [1, 2]. Numerous studies have shown that the expression of miRNAs is deregulated and these miRNAs act as regulatory molecules in many biological processes, including differentiation, proliferation, and apoptosis of tumor cells [3,4,5]. Several miRNAs are downregulated in many tumors and appear to function as tumor suppressor genes [6]. Among these downregulated miRNAs, miR-101 is one of the most downregulated miRNAs in human cancers, multiple research studies have been exploring the prognostic
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
